Group 1 - The stock price of Baihe Co., Ltd. on July 29 was 43.03 yuan, down 1.00 yuan or 2.27% from the previous trading day [1] - The opening price on that day was 44.88 yuan, with a highest price of 45.00 yuan and a lowest price of 42.84 yuan, resulting in a trading volume of 102 million yuan [1] - The company announced a cash dividend distribution plan for the fiscal year 2024, proposing a cash dividend of 0.75 yuan per share (tax included), with the record date set for August 4, 2025, and the ex-dividend date on August 5 [1] Group 2 - Baihe Co., Ltd. operates in the food and beverage, pet economy, cosmetics, and vitamin-related products sectors, and is registered in Shandong [1] - On July 29, the net outflow of main funds was 28.6257 million yuan, accounting for 1.85% of the circulating market value [1]

金融界消息 截至2025年7月29日收盘，百合股份（603102）报收于43.03元，下跌2.27%，换手率 6.55%，成交量2.35万手，成交金额1.02亿元。 百合股份最新一期业绩显示，截至2025一季报，公司营业总收入2.07亿元、同比增长9.75%，归属净利 润3520.58万元，同比增长1.02%，扣非净利润3500.87万元，同比增长0.80%，流动比率7.275、速动比率 6.650、资产负债率11.46%。 天眼查商业履历信息显示，威海百合生物技术股份有限公司，成立于2005年，位于威海市，是一家以从 事化学原料和化学制品制造业为主的企业。企业注册资本6400万人民币，实缴资本4074.4035万人民 币。公司法定代表人为刘新力。 通过天眼查大数据分析，威海百合生物技术股份有限公司共对外投资了6家企业，参与招投标项目86 次，知识产权方面有商标信息898条，专利信息408条，此外企业还拥有行政许可4052个。 资金流向方面，今日主力资金净流出2862.57万元，占比成交额28.03%。其中，超大单净流出71.51万 元、占成交额0.7%，大单净流出2791.06万元、占成交额27.33%，中 ...

广发证券股份有限公司 关于威海百合生物技术股份有限公司差异化权益分派 事项的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐人"）作为威海百 合生物技术股份有限公司（以下简称"百合股份"、"上市公司"或"公司"）首 次公开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》《上海证券交易所上市公司自律监管指南第 2 号—业务办理》等相关法律法 规的要求，对百合股份差异化权益分派事项进行了审慎核查，具体情况如下： 《上海证券交易所 上市公司自律监管指引第 7 号—回购股份》等相关法律法规、规范性文件和《公 司章程》的相关规定，公司已回购股份不参与利润分配。基于以上情况，造成公 司本次权益分派实施时股权登记日的总股本与实际参与分配的股份总数存在差 异。因此，公司 2024 年度利润分配实施差异化分红。 二、股东会审议通过的差异化权益分派的方案及调配现金分红总额 公司于2025年6月6日召开了2024年年度股东大会，审议通过了《关于公司 净利润139,309,114.98元，截 至2024年12 月31日，公司 ...

（文章来源：证券日报） 证券日报网讯 7月29日晚间，百合股份发布公告称，2024年年度权益分派方案为A股每股现金红利0.75 元（含税），股权登记日为2025年8月4日，除权（息）日为2025年8月5日。 ...

广发证券股份有限公司 关于威海百合生物技术股份有限公司差异化权益分派 事项的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐人"）作为威海百 合生物技术股份有限公司（以下简称"百合股份"、"上市公司"或"公司"）首 次公开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》《上海证券交易所上市公司自律监管指南第 2 号—业务办理》等相关法律法 规的要求，对百合股份差异化权益分派事项进行了审慎核查，具体情况如下： 一、本次差异化权益分派的原因 公司于 2024 年 8 月 8 日召开第四届董事会第九次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，并于 2024 年 8 月 15 日披露了 《关于以集中竞价交易方式回购公司股份的回购报告书》，拟回购公司股份资金 总额不低于人民币 3000 万元（含），不超过人民币 6000 万元（含），回购期限自 公司董事会审议通过本次回购方案之日起 12 个月内。 公司于 2025 年 7 月 16 日披露《威海百合生物技术股份有限公司关于股份回 购比 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-029 威海百合生物技术股份有限公司 重要内容提示： 2024年年度权益分派实施公告 每股分配比例 A 股每股现金红利0.75元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/4 | — | 2025/8/5 | 2025/8/5 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次利润分配方案经公司2025 年 6 月 6 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 差异化分红送转方案： 公司在 2024 年年度利润分配预案公告披露后，截止 2025 年 7 月 15 日，公司以集中竞价 交易方式回 ...

从资金流向上来看，当日食品加工板块主力资金净流出1.27亿元，游资资金净流出2488.55万元，散户资 金净流入1.52亿元。食品加工板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 603345 | 安井食品 | | 3588.42万 | 9.81% | -3645.99万 | -9.97% | 57.57万 | 0.16% | | 002515 | 金字火腿 | | 2249.10万 | 14.02% | -1481.85万 | -9.24% | -767.25万 | -4.78% | | 002702 海欣食品 | | | 1308.54万 | 13.69% | -383.06万 | -4.01% | -925.48万 | -9.68% | | 002626 | 金达威 | | 1100.54万 | 4.62% | 1399.42万 | 5.88% | -2499.96 ...

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 学大教育 | 000526 | 股权激励限售流通 | 127.62万 | | 亚钾国际 | 000893 | 增发A股原股东配售上市 | 1.11亿 | | 上海电力 | 600021 | 增发A股原股东配售上市 | 2亿 | | 四川路桥 | 600039 | 股权激励限售流通 | 367.08万 | | 海正药业 | 600267 | 股权激励限售流通 | 703.09万 | | 申能股份 | 600642 | 股权激励限售流通 | 25.84万 | | 中泰化学 | 002092 | 股权激励限售流通 | 355.35万 | | 沧州明珠 | 002108 | 股权激励限售流通 | 700.77万 | | 常润股份 | 603201 | 发行前股份限售流通 | 6539.4万 | | 盛新锂能 | 002240 | 股权激励限售流通 | 296.7万 | | 川发龙蟒 | 002312 | 股权激励限售流通 | 35.59万 | | 华星创业 | 300025 | 增发A股原股东配售上市 ...

Core Viewpoint - The demand for health and weight loss has driven the penetration of nutritional functional foods, leading to the rise of contract manufacturing companies in the industry, exemplified by Hengmei Health's successful IPO application and market position [1][3]. Group 1: Company Overview - Hengmei Health holds a leading position in the nutritional functional food contract manufacturing market with a 4.2% market share, serving notable clients such as WonderLab and Liangpinpuzi [3]. - The company has experienced significant revenue growth, with sales increasing from 578 million yuan in 2022 to 1.072 billion yuan in 2024, and net profit rising 1.5 times to 100 million yuan [17]. - Hengmei Health has established a strong patent portfolio with 56 invention patents and over 5,000 personalized product formulas [17]. Group 2: Market Dynamics - The nutritional functional food sector has seen a surge in new brands, with the number of meal replacement brands increasing from 2,837 in 2019 to 3,540 in 2020, driven by rising health awareness and investment in the consumer sector [13]. - The company has shifted its contract manufacturing model from OEM to ODM, providing comprehensive services from product planning to marketing support [14]. Group 3: Financial Performance - In 2024, the company's revenue is projected to grow by 9.5% to 1.072 billion yuan, although this represents a significant decline from the 67% growth seen in 2023 [4]. - The first quarter of 2025 shows continued pressure with revenue of 217 million yuan, reflecting nearly a 10% decline year-on-year and quarter-on-quarter [5]. Group 4: Strategic Challenges - Hengmei Health's performance is highly dependent on the stability of its downstream brand partners, with some clients seeking to reduce reliance on contract manufacturing [21]. - The company faces potential risks from key clients transitioning to self-manufacturing, as seen with WonderLab's shift towards probiotics and self-production capabilities [22]. - The company is investing in new product lines, such as "nutritional beans," to capture market opportunities, but faces challenges related to rising raw material costs and market uncertainties [27].

Core Insights - The aging population and the silver economy are driving a surge in the health and wellness sector, leading to a wave of IPOs from companies targeting this demographic [1][2][3] Group 1: Market Trends - By 2025, the number of elderly individuals aged 60 and above in China is expected to exceed 300 million, accounting for 22% of the population, creating unprecedented opportunities in the health industry [2] - The health industry is projected to reach a market size of approximately 11.5 to 12 trillion yuan in 2024, with a year-on-year growth of 9% to 10%, largely driven by aging [4] Group 2: Company Performances - Hengmei Health, a nutritional functional food producer, reported revenue growth from 587 million yuan in 2022 to 1.071 billion yuan in 2024, nearly doubling its revenue, with a net profit increase of 139.5% [6][7] - Haipai Ke, which previously focused on maternal and infant products, is expanding into family consumption, particularly targeting the elderly market, with its dietary supplement business growing over 14 times from 5.06 million yuan in 2022 to 72.43 million yuan in 2024 [15][16] Group 3: Product Innovations - Hengmei Health is focusing on the silver economy by developing products tailored to the nutritional needs of the elderly, such as fish oil protein powder and glucosamine milk powder [7][9] - Companies like Xianle Health and Baihe Co. are also innovating in the silver health product space, offering solutions for heart health, blood lipid management, and joint health [8] Group 4: Healthcare Integration - The demand for integrated medical and health services for the elderly is rising, with companies like Tongrentang Medical and Puxiang Health focusing on providing comprehensive care solutions [21][22] - Tongrentang Medical reported revenue growth from 910 million yuan in 2022 to 1.175 billion yuan in 2024, transitioning from a net loss to a profit of 46.2 million yuan [23] Group 5: AI and Technology - The integration of AI in healthcare is becoming a trend, with companies like Weimai leveraging AI for full-course management of elderly patients, enhancing the connection between diagnosis, treatment, and rehabilitation [31][34] - Weimai's revenue grew from 511 million yuan in 2022 to 652 million yuan in 2024, with its full-course management services accounting for 72% of its revenue [34]